A phase II study to evaluate ZD1839 (Iressa) in second line combination with paclitaxel (taxol) and carboplatin (paraplatin) in patients with advanced ovarian, peritoneal or fallopian tube adenocarcinoma

Study identifier:1839IL/0074

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A phase II study to evaluate ZD1839 (Iressa) in second line combination with paclitaxel (taxol) and carboplatin (paraplatin) in patients with advanced ovarian, peritoneal or fallopian tube adenocarcinoma

Medical condition

cancer

Phase

Phase 2

Healthy volunteers

-

Study drug

-

Sex

-

Actual enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Mar 2002
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria